ATE512232T1 - Expressionssystem mit einem säuger-beta-actin- promotor - Google Patents

Expressionssystem mit einem säuger-beta-actin- promotor

Info

Publication number
ATE512232T1
ATE512232T1 AT04819918T AT04819918T ATE512232T1 AT E512232 T1 ATE512232 T1 AT E512232T1 AT 04819918 T AT04819918 T AT 04819918T AT 04819918 T AT04819918 T AT 04819918T AT E512232 T1 ATE512232 T1 AT E512232T1
Authority
AT
Austria
Prior art keywords
promoter
promoters
actin promoter
expression system
mammalian
Prior art date
Application number
AT04819918T
Other languages
English (en)
Inventor
Hiroyuki Tsunoda
Kiyoshi Habu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE512232T1 publication Critical patent/ATE512232T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AT04819918T 2003-12-03 2004-12-03 Expressionssystem mit einem säuger-beta-actin- promotor ATE512232T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003405269 2003-12-03
PCT/JP2004/018006 WO2005054467A1 (ja) 2003-12-03 2004-12-03 哺乳類βアクチンプロモーターを利用した発現系

Publications (1)

Publication Number Publication Date
ATE512232T1 true ATE512232T1 (de) 2011-06-15

Family

ID=34650208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819918T ATE512232T1 (de) 2003-12-03 2004-12-03 Expressionssystem mit einem säuger-beta-actin- promotor

Country Status (9)

Country Link
US (1) US8298816B2 (de)
EP (2) EP2270152A1 (de)
JP (2) JPWO2005054467A1 (de)
KR (1) KR20060123413A (de)
CN (1) CN1914320A (de)
AT (1) ATE512232T1 (de)
AU (1) AU2004295590B2 (de)
CA (1) CA2548185A1 (de)
WO (1) WO2005054467A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512782A (ja) * 2006-12-20 2010-04-30 ジ チャン ユウ， Ｈｉｖのｎｃ蛋白質発現用ベクター及びこれを利用したｎｃ蛋白質の生産方法
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
JP2010104326A (ja) * 2008-10-31 2010-05-13 Japan Health Science Foundation 加齢黄斑変性モデル動物、及び、その作成方法
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
FR2981946B1 (fr) * 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
FR2986536A1 (fr) * 2012-02-08 2013-08-09 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (cho)
EP2684959A1 (de) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vektoren zur Transformation von Mycoplasma hyopneumoniae, transformierte Stämme von Mycoplasma hyopneumoniae, sowie deren Verwendung
CN103525868B (zh) * 2013-10-17 2015-01-21 百泰生物药业有限公司 哺乳动物细胞高效表达载体的构建及应用
CN103525867B (zh) * 2013-10-17 2015-01-21 北京东方百泰生物科技有限公司 用于高表达细胞株开发的载体的构建及应用
CN105037560B (zh) * 2015-08-06 2019-02-05 中国农业科学院生物技术研究所 培育表达shTRAIL植物的方法
WO2020059848A1 (ja) * 2018-09-20 2020-03-26 国立大学法人東京医科歯科大学 レンチウイルスベクター産生の増強方法
CN110484563B (zh) * 2019-07-25 2023-04-07 新乡医学院 哺乳动物细胞组合表达载体、表达系统、制备方法和应用
WO2022066849A1 (en) * 2020-09-24 2022-03-31 University Of Massachusetts Aav vectors encoding nf1 and uses thereof
CN112481418A (zh) * 2020-12-25 2021-03-12 湖南丰晖生物科技有限公司 一种实时荧光定量pcr引物及其应用
KR102737145B1 (ko) 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도
KR102737146B1 (ko) 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
AU629554B2 (en) * 1988-06-24 1992-10-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Exogenous gene expression vector containing chick beta-actin gene promoter
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2126101A1 (en) 1991-12-17 1993-06-24 Robert J. Debs Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
DE19516776A1 (de) * 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9819912D0 (en) * 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
AU2001290984A1 (en) 2000-09-18 2002-04-02 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
DE10128832A1 (de) 2001-06-15 2003-02-06 Jochen Reis Vektor und dessen Verwendung in gentherapeutischen Verfahren
NZ535100A (en) 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
AU2003231230A1 (en) 2002-05-01 2003-11-17 University Of Florida Research Foundation, Inc. Improved raav expression systems and methods for enhancing transduction of mammalian neural cells
ATE446077T1 (de) 2002-05-02 2009-11-15 Univ Rochester Vektoren mit beiden isoformen von beta- hexosaminidase
US20030224477A1 (en) * 2002-05-31 2003-12-04 Heartlein Michael W. Optimized promoter constructs
US20060099709A1 (en) 2002-10-01 2006-05-11 Chuan-Yuan Li Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
DK2332972T3 (en) * 2003-06-24 2018-04-23 Genzyme Corp Hitherto UNKNOWN BETA-ACTIN AND RPS21 PROMOTORS AND APPLICATIONS

Also Published As

Publication number Publication date
AU2004295590A1 (en) 2005-06-16
KR20060123413A (ko) 2006-12-01
EP1707629A1 (de) 2006-10-04
JPWO2005054467A1 (ja) 2007-12-06
EP1707629B1 (de) 2011-06-08
EP1707629A4 (de) 2007-12-12
CN1914320A (zh) 2007-02-14
AU2004295590B2 (en) 2010-04-29
CA2548185A1 (en) 2005-06-16
US8298816B2 (en) 2012-10-30
JP2012070744A (ja) 2012-04-12
EP2270152A1 (de) 2011-01-05
WO2005054467A1 (ja) 2005-06-16
US20080250514A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
ATE512232T1 (de) Expressionssystem mit einem säuger-beta-actin- promotor
Rowe et al. De novo DNA methylation of endogenous retroviruses is shaped by KRAB-ZFPs/KAP1 and ESET
FI3546585T3 (fi) Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa
ATE225853T1 (de) Gewebe-spezifische promotoren
EP4541783A3 (de) Herstellung von terephthalsäureestern
EA201791991A1 (ru) Способ улучшения способности противодействовать внедренным днк-содержащим вирусам растения
Yi et al. Long noncoding RNA and its role in virus infection and pathogenesis
Benabdellah et al. A chimeric HS4-SAR insulator (IS2) that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem cells
RU2011126248A (ru) Способ карбонилирования для получения метилацетата
Suzuki et al. Human artificial chromosomes constructed using the bottom-up strategy are stably maintained in mitosis and efficiently transmissible to progeny mice
EP4196263C0 (de) Verfahren zur herstellung von geträgerten metall-katalysatoren mit einer als katalysatorträger eingesetzten kornförmigen aktivkohle
DE502004001431D1 (de) Verfahren zur herstellung von phthalsäureanhydrid
ATE391768T1 (de) Verpackungszelle
FI4008789T3 (fi) Bikistroninen AAV-vektori RNA-häiriöille ALS:ssä
AR019906A2 (es) Proceso para la produccion de acetato de vinilo mediante la reaccion de etileno, oxigeno y acido acetico como reactivos.
Rasschaert et al. Specific transcriptional and post-transcriptional regulation of the major immediate early ICP4 gene of GaHV-2 during the lytic, latent and reactivation phases
Ge et al. Optimization of eGFP expression using a modified baculovirus expression system
WO2010099169A3 (en) A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
Katzenberger et al. The Drosophila translational control element (TCE) is required for high-level transcription of many genes that are specifically expressed in testes
DK0527785T3 (da) Forbedringer angående detektionen af vira
Šenigl et al. The core element of a CpG island protects avian sarcoma and leukosis virus-derived vectors from transcriptional silencing
Strassheim et al. Oncogenic Marek’s disease herpesvirus encodes an isoform of the conserved regulatory immediate early protein ICP27 generated by alternative promoter usage
EA201791297A1 (ru) Полиэтиленовая композиция и труба, содержащая в своем составе такую композицию
Fujimoto et al. Antiviral effects against influenza A virus infection by a short hairpin RNA targeting the non-coding terminal region of the viral nucleoprotein gene
Bender et al. Low titer lentiviral transgenesis in rodents with simian immundeficiency virus vector

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties